LENZ Therapeutics updates board and audit roles
LENZ Therapeutics, Inc. reports changes to its Board of Directors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
LENZ Therapeutics, Inc. reports changes to its Board of Directors. On June 30, 2026, director Zach Scheiner resigned from the Board and all its committees, effective immediately.
The company states his resignation did not arise from any dispute or disagreement over its operations, policies or practices. On the same date, the Board reduced its size to six members and appointed Jeff George to the Audit Committee, which now consists of Shelley Thunen, Frederic Guerard and Jeff George.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation date: June 30, 2026
Board size after change: 6 directors
Audit Committee members: 3 members
+1 more
4 metrics
Resignation date
June 30, 2026
Effective resignation of director Zach Scheiner
Board size after change
6 directors
Board reduced in size following resignation
Audit Committee members
3 members
Shelley Thunen, Frederic Guerard, Jeff George
Filing signatory title
Chief Financial Officer
Role of Daniel Chevallard signing the report
Key Terms
Board of Directors, Audit Committee, Emerging growth company, principal financial and accounting officer
4 terms
Board of Directors financial
"his resignation as a member of the Company’s Board of Directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Audit Committee financial
"the Board appointed Jeff George to its audit committee (the “Audit Committee”)"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
principal financial and accounting officer financial
"Chief Financial Officer (Principal Financial and Accounting Officer)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did LENZ (LENZ) disclose in this 8-K filing?
LENZ disclosed that director Zach Scheiner resigned from its Board and all committees, effective June 30, 2026. The company emphasized his departure was not due to any dispute or disagreement regarding operations, policies, or practices, and acknowledged his valuable service to the organization.
Did LENZ (LENZ) report any disagreement behind Dr. Scheiner’s resignation?
LENZ stated that Dr. Scheiner’s resignation was not the result of any dispute or disagreement with the company. This includes matters related to operations, policies, or practices, suggesting the departure reflects a routine governance change rather than a conflict-driven event.
How did LENZ (LENZ) adjust its Board size after the resignation?
Following Dr. Scheiner’s resignation on June 30, 2026, LENZ’s Board reduced its size to six directors. This reduction reflects the vacancy created and indicates the company chose not to immediately add another director to maintain the prior board size.
What change did LENZ (LENZ) make to its Audit Committee?
On June 30, 2026, LENZ appointed Jeff George to its Audit Committee. After this appointment, the Audit Committee members are Shelley Thunen, Frederic Guerard, and Jeff George, clarifying the committee’s composition following Dr. Scheiner’s departure from the Board.
Who signed the LENZ (LENZ) 8-K reporting these board changes?
The 8-K was signed on behalf of LENZ Therapeutics, Inc. by Daniel Chevallard. He is identified as the company’s Chief Financial Officer and serves as the principal financial and accounting officer under the Securities Exchange Act requirements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
